Summary
LUNG cancer patients in Scotland are to be denied access to a life expectancy increasing drug because it does not represent value for money.
The Scottish Medicines Consortium (SMC), the body that advises which drugs should be prescribed by the NHS, yesterday announced it will not recommend the use of Gefitinib.See the full content of this document
Extract
Fury As Scots Miss Out On Cancer Drug
Campaigners have critici...
See the full content of this document
Sponsored links
